Get started
Voyager Therapeutics, Inc.Voyager Therapeutics, Inc.Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VYGR chart


Full chart

VYGR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪388.82 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
24.78
Basic EPS (TTM)
0.32 USD
Net income (FY)
‪132.33 M‬ USD
Revenue (FY)
‪250.01 M‬ USD
Shares float
‪45.09 M‬
Beta (1Y)
0.97

Employees


Employees (FY)
162
Change (1Y)
+37 +29.60%
Revenue / Employee (1Y)
‪1.54 M‬ USD
Net income / Employee (1Y)
‪816.85 K‬ USD

About Voyager Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alfred W. Sandrock
Website
voyagertherapeutics.com
Headquarters
Lexington
Founded
2013
FIGI
BBG005ZSY233
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

VYGR news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VYGR is 7.13 USD — it has increased by 0.42% in the past 24 hours. Watch Voyager Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Voyager Therapeutics, Inc. stocks are traded under the ticker VYGR.
VYGR stock has risen by 4.70% compared to the previous week, the month change is a 1.13% rise, over the last year Voyager Therapeutics, Inc. has showed a 4.24% increase.
We've gathered analysts' opinions on Voyager Therapeutics, Inc. future price: according to them, VYGR price has a max estimate of 30.00 USD and a min estimate of 7.00 USD. Watch VYGR chart and read a more detailed Voyager Therapeutics, Inc. stock forecast: see what analysts think of Voyager Therapeutics, Inc. and suggest that you do with its stocks.
VYGR reached its all-time high on Mar 5, 2018 with the price of 31.91 USD, and its all-time low was 2.46 USD and was reached on Oct 5, 2021. View more price dynamics on VYGR chart.
See other stocks reaching their highest and lowest prices.
VYGR stock is 3.75% volatile and has beta coefficient of 0.97. Track Voyager Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Voyager Therapeutics, Inc. there?
Today Voyager Therapeutics, Inc. has the market capitalization of ‪388.82 M‬, it has increased by 4.03% over the last week.
Yes, you can track Voyager Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Voyager Therapeutics, Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
VYGR earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.41 USD resulting in a 56.00% surprise. The estimated earnings for the next quarter are −0.44 USD per share. See more details about Voyager Therapeutics, Inc. earnings.
Voyager Therapeutics, Inc. revenue for the last quarter amounts to ‪29.58 M‬ USD, despite the estimated figure of ‪9.51 M‬ USD. In the next quarter, revenue is expected to reach ‪11.70 M‬ USD.
VYGR net income for the last quarter is ‪−10.14 M‬ USD, while the quarter before that showed ‪−11.33 M‬ USD of net income which accounts for 10.49% change. Track more Voyager Therapeutics, Inc. financial stats to get the full picture.
No, VYGR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 162.00 employees. See our rating of the largest employees — is Voyager Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Voyager Therapeutics, Inc. EBITDA is ‪−1.78 M‬ USD, and current EBITDA margin is 50.58%. See more stats in Voyager Therapeutics, Inc. financial statements.
Like other stocks, VYGR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Voyager Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Voyager Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Voyager Therapeutics, Inc. stock shows the sell signal. See more of Voyager Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.